Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 February 2022 | Story NONSINDISO QWABE | Photo Thabiso Mdakana
Qwaqwa Campus vaccination drive
Andile Tshabalala and Theodore Hlalele, CSRC Qwaqwa Campus.

As the University of the Free State is encouraging staff and students to be vaccinated in order for all of us to return to campus life as we know it, the Qwaqwa Campus held its first in-person vaccination activation drive for its first and returning students. The drive was to further encourage students to vaccinate, and to keep themselves and others safe by educating themselves.

The cheerful and excited crowd of more than 100 students were gathered at the Amphitheatre on campus, where they got to know more about the COVID-19 Regulations and Required Vaccination Policy and interacted with Department of Health officials to understand more about the jabs and booster shots.

No one is forced, but everyone is encouraged

The university’s approved policy came into effect on 14 February, requiring staff and students to be vaccinated as a measure towards ensuring everyone’s smooth return to its three campuses. However, as Qwaqwa Campus Principal Dr Martin Mandew highlighted, “no one is being forced to vaccinate, but we are all strongly encouraged to do so”.

Dr Mandew said the student experience is too rich and vibrant to be confined to virtual learning. He showed students his own vaccination certificate, quoting a Zulu proverb, ‘indlela ibuzwa kwabaphambili’, which loosely translated means ‘those who have gone before you can show the way’.

“If you are not vaccinated, it will be impossible for us to enjoy face-to-face interaction again. Ask yourself: ‘If the principal is vaccinated, who am I not to be?” he said.

The lively drive also kept students entertained through live performances by local artists. 

Students could also raise pressing issues and questions with Department of Health officials – including common side effects, apathy against vaccination due to religious beliefs, the efficacy of the vaccine to protect against COVID-19, and the implementation of the UFS Vaccination Policy. 

The programme line-up also included messages of support from the Director: Student Affairs, Zoleka Dotwana, the Deputy Director of Housing and Residences, Zakhele Mdluli, and UVPERSU Vice-Chairperson, Dr Grey Magaiza.

The operating days of the on-campus vaccination site have been extended to accommodate streams of incoming students who still want to be vaccinated. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept